Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis

For studies that provided the patients' raw data (detailed information for each patient), data on patients' age, sex, asthma history, pretreatment IgE concentration, pretreatment and posttreatment severity of eczema (using Severity Scoring of Atopic Dermatitis [SCORAD], Eczema Area and Sev...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2016-12, Vol.138 (6), p.1719-1722.e1
Main Authors: Wang, Hsiao-Han, MD, Li, Yu-Chuan, MD, PhD, Huang, Yu-Chen, MD
Format: Article
Language:English
Subjects:
Allergies
Allergy and Immunology
Asthma
Dermatitis
Eczema
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For studies that provided the patients' raw data (detailed information for each patient), data on patients' age, sex, asthma history, pretreatment IgE concentration, pretreatment and posttreatment severity of eczema (using Severity Scoring of Atopic Dermatitis [SCORAD], Eczema Area and Severity Index [EASI], or Investigators' Global Assessment [IGA] scores), clinical response, adverse event, and treatment duration were collected (Table II). The association of serum IgE concentrations of less than 700 IU/mL with more favorable clinical responses in this analysis might be explained by better IgE neutralization in patients with lower concentrations of IgE under fixed dosages.\n One dropout Systemic steroids, Csa/topical steroid only OMA can be considered for refractory AD if total IgE level falls within the range of neutralization by the mAb Table I Summary of included studies Csa, Cyclosporin A; ISA, immunosuppressants; NA, no data available; OMA, omalizumab; TARC, thymus and activation-regulated chemokine; TSLP, thymic stromal lymphopoietin; q2w or q3w, in 2-wk or 3-wk interval; UV, ultraviolet light treatment.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.05.038